CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
N-acetylcysteine and ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00611897
NCT00611897Phase 2Completed
CompareCT.gov

N-acetylcysteine and NMDA Antagonist Interactions

Yale University·interventional·Posted Feb 11, 2008·Updated May 8, 2015

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine and ketamine and placebo and ketamine for Cognitive Dysfunction. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Dysfunction
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2008
Enrollment StartJan 1, 2006
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 18.4 years ago

Interventions

N-acetylcysteine and ketaminedrug

Active drug (N-acetylcysteine)

placebo and ketaminedrug

placebo N-acetylcysteine